Doxycycline directly targets PAR1 to suppress tumor progression

Doxycycline have been reported to exert anti-cancer activity and have been assessed as anti-cancer agents in clinical trials. However, the direct targets of doxycycline in cancer cells remain unclear. In this study, we used a chemical proteomics approach to identify the Protease-activated receptor 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhong, Weilong, Chen, Shuang, Zhang, Qiang, Xiao, Ting, Qin, Yuan, Gu, Ju, Sun, Bo, Liu, Yanrong, Jing, Xiangyan, Hu, Xuejiao, Zhang, Peng, Zhou, Honggang, Sun, Tao, Yang, Cheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5370004/
https://www.ncbi.nlm.nih.gov/pubmed/28187433
http://dx.doi.org/10.18632/oncotarget.15166

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5370004/
https://www.ncbi.nlm.nih.gov/pubmed/28187433
http://dx.doi.org/10.18632/oncotarget.15166

Ejemplares similares